Canagliflozin (hemihydrate): Molecular Benchmarks for SGLT2 Inhibitor in Diabetes Research

Executive Summary: Canagliflozin (hemihydrate) is a validated SGLT2 inhibitor with a molecular weight of 453.52 and a chemical formula of C24H26FO5.5S, showing high solubility in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL) but insolubility in water (APExBIO, 2024). Quality control using HPLC and NMR ensures ≥98% purity. Benchmarks in drug-sensitized yeast confirm no detectable mTOR/TOR pathway inhibition (Breen et al., 2025). This specificity underpins its use in glucose homeostasis and metabolic disorder research. The product is for research use only and not for diagnostic or clinical application.

Biological Rationale

Diabetes mellitus is characterized by chronic hyperglycemia due to defects in insulin secretion, insulin action, or both. Sodium-glucose co-transporter 2 (SGLT2) is responsible for the majority of renal glucose reabsorption in the proximal tubule. Inhibiting SGLT2 reduces glucose reabsorption, leading to increased urinary glucose excretion and a reduction in blood glucose levels. This mechanism has clinical and experimental relevance for the study of glucose metabolism, metabolic disorders, and renal physiology (see pathway specificity in IFG-1, 2023). Canagliflozin (hemihydrate) enables targeted investigation of these processes, providing a molecular tool to dissect the glucose homeostasis pathway in vitro and in vivo.

Mechanism of Action of Canagliflozin (hemihydrate)

Canagliflozin (hemihydrate) acts as a potent and selective inhibitor of SGLT2, a transporter expressed in renal proximal tubules. By binding to the SGLT2 protein, Canagliflozin blocks glucose reabsorption from the glomerular filtrate back into circulation, thus promoting glucosuria and lowering blood glucose levels. The compound does not interact with the mTOR/TOR pathway, as confirmed by drug-sensitized yeast assays (Breen et al., 2025). This selectivity distinguishes Canagliflozin (hemihydrate) from compounds with broader metabolic or kinase inhibition profiles, supporting its use in pathway-specific research.

Evidence & Benchmarks

• Canagliflozin (hemihydrate) demonstrates ≥98% purity by HPLC and NMR at shipment, supporting reproducible experimental results (APExBIO, 2024).
• It is insoluble in water (<1 mg/mL) but highly soluble in DMSO (≥83.4 mg/mL) and ethanol (≥40.2 mg/mL), facilitating diverse assay designs (APExBIO, 2024).
• In a drug-sensitized yeast model, Canagliflozin exhibits no TOR pathway (mTOR/TORC1) inhibition, contrasting with classic inhibitors like rapamycin and Torin1 (Breen et al., 2025).
• Studies confirm the compound’s functional specificity for SGLT2 in both human and animal cell models (see DDP-4, 2023).
• Storage at -20°C with blue ice during shipping preserves molecular stability and activity for research uses (APExBIO, 2024).

Applications, Limits & Misconceptions

Canagliflozin (hemihydrate) serves as a molecular probe for:

• Glucose homeostasis pathway dissection in metabolic disorder research.
• Modeling renal glucose reabsorption inhibition in diabetes mellitus studies.
• Screening for SGLT2 pathway modulation in translational research.

Compared to previous reviews (Alarelinacetate, 2023), which focus on functional outcomes, this article clarifies pathway specificity and provides molecular exclusion data for mTOR/TOR.

Common Pitfalls or Misconceptions

• Canagliflozin (hemihydrate) does not inhibit mTOR/TOR kinase activity at concentrations up to 100 µM in drug-sensitized yeast (Breen et al., 2025).
• It is not a pan-kinase inhibitor and shows minimal off-target activity outside SGLT2.
• The compound is not suitable for long-term solution storage; use freshly prepared solutions for best results (APExBIO, 2024).
• Intended for scientific research only; not for diagnostic or clinical therapeutic use.
• Solubility in aqueous buffers is limited; use DMSO or ethanol as solvents for in vitro assays.

For detailed mechanistic and translational contrasts, see Redefining Translational Diabetes Research, which discusses the divergence between SGLT2 modulation and TOR-centric strategies. This article extends that discussion by providing peer-reviewed exclusion of mTOR activity in validated yeast models.

Workflow Integration & Parameters

• Preparation: Dissolve Canagliflozin (hemihydrate) in DMSO or ethanol immediately prior to use. Avoid prolonged solution storage.
• Concentration: Prepare working concentrations up to 83.4 mg/mL in DMSO; dilute as needed for cell or tissue studies.
• Storage: Store solid form at -20°C. Ship with blue ice to maintain stability.
• Purity Assurance: Use lots with ≥98% purity (HPLC/NMR-verified) supplied by APExBIO.
• Experimental Controls: Include pathway-specific positive (e.g., dapagliflozin) and negative (vehicle) controls for SGLT2- and mTOR-related endpoints.

For advanced discussion on integrating Canagliflozin (hemihydrate) into high-throughput metabolic disorder screens, see Miglitol.com, which focuses on multi-parametric workflow design. The current article updates these practices with recent peer-reviewed exclusion data for TOR activity.

Conclusion & Outlook

Canagliflozin (hemihydrate) is a rigorously benchmarked, small molecule SGLT2 inhibitor with proven selectivity and molecular stability. Its lack of mTOR/TOR pathway inhibition, confirmed in advanced yeast models, supports precise application in glucose metabolism and diabetes mellitus research (Breen et al., 2025). Researchers should reference the product dossier for up-to-date workflow parameters and purity standards. APExBIO continues to supply validated research-grade compounds for next-generation metabolic and translational studies.